U
14.20
0.42 (3.05%)
| Previous Close | 13.78 |
| Open | 14.00 |
| Volume | 1,017,054 |
| Avg. Volume (3M) | 1,114,973 |
| Market Cap | 767,891,968 |
| Price / Earnings (Forward) | 27.93 |
| Price / Sales | 35.62 |
| Price / Book | 23.47 |
| 52 Weeks Range | |
| Earnings Date | 27 Feb 2025 |
| Operating Margin (TTM) | -2,815.25% |
| Diluted EPS (TTM) | -4.38 |
| Quarterly Revenue Growth (YOY) | -81.50% |
| Total Debt/Equity (MRQ) | 1,522.46% |
| Current Ratio (MRQ) | 11.99 |
| Operating Cash Flow (TTM) | -166.25 M |
| Levered Free Cash Flow (TTM) | -122.89 M |
| Return on Assets (TTM) | -15.64% |
| Return on Equity (TTM) | -241.16% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | uniQure N.V. | Bullish | Bullish |
AIStockmoo Score
0.3
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -2.0 |
| Average | 0.25 |
|
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 6.09% |
| % Held by Institutions | 91.95% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 70.00 (HC Wainwright & Co., 392.96%) | Buy |
| Median | 38.00 (167.61%) | |
| Low | 28.00 (Guggenheim, 97.18%) | Buy |
| Average | 45.33 (219.23%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 14.17 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Chardan Capital | 30 May 2025 | 38.00 (167.61%) | Buy | 14.47 |
| 12 May 2025 | 38.00 (167.61%) | Buy | 13.15 | |
| HC Wainwright & Co. | 29 May 2025 | 70.00 (392.96%) | Buy | 14.90 |
| 21 Apr 2025 | 70.00 (392.96%) | Buy | 13.29 | |
| Guggenheim | 12 May 2025 | 28.00 (97.18%) | Buy | 13.15 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 11 Jun 2025 | Announcement | uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer |
| 02 Jun 2025 | Announcement | uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease |
| 29 May 2025 | Announcement | uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE) |
| 09 May 2025 | Announcement | uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress |
| 05 May 2025 | Announcement | uniQure to Announce First Quarter 2025 Financial Results |
| 17 Apr 2025 | Announcement | uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |